Resveratrol suppresses proliferation and induces apoptosis of uterine sarcoma cells by inhibiting the Wnt signaling pathway.
Wnt signaling pathway
glycogen synthase kinase-3β
resveratrol
uterine sarcoma
β-catenin
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
15
10
2018
accepted:
13
12
2018
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
15
3
2019
Statut:
ppublish
Résumé
Resveratrol, a natural product and peroxisome proliferator-activated receptor (PPAR) agonist, has been reported to exert anti-cancer effects in several tumor models. A previous study by our group reported that prostaglandin J2, a PPARγ ligand, inhibited cell proliferation in a uterine sarcoma cell line. The aim of the present study was to investigate the role of the Wnt signaling pathway in resveratrol-induced apoptosis and inhibition of cell proliferation in the MES-SA human uterine sarcoma cell line. A WST-1 assay demonstrated that resveratrol inhibited cell proliferation in the MES-SA cell line, and flow cytometry revealed that the number of apoptotic cells increased in a resveratrol dose-dependent manner. The mechanisms underlying these effects of resveratrol were speculated to involve the expression of β-catenin and its target gene, c-myc, which were examined using western blot analysis. The results revealed a dose-dependent downregulation of this β-catenin and c-myc. This effect was blunted by a pharmacological inhibitor of glycogen synthase kinase 3β. Therefore, it is likely that resveratrol inhibited the cell proliferation and increased the number of apoptotic cells, at least partially, via the Wnt signaling pathway. The present results suggest that resveratrol is a potential candidate for the treatment of uterine sarcoma.
Identifiants
pubmed: 30867708
doi: 10.3892/etm.2019.7209
pii: ETM-0-0-7209
pmc: PMC6396019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2242-2246Références
Pharm Res. 2002 Dec;19(12):1907-14
pubmed: 12523673
Cancer Sci. 2003 Mar;94(3):225-9
pubmed: 12824913
Annu Rev Cell Dev Biol. 2004;20:781-810
pubmed: 15473860
Bull Cancer. 2004 May;91 Suppl 2:S99-108
pubmed: 15899633
Nat Rev Drug Discov. 2006 Dec;5(12):997-1014
pubmed: 17139285
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1246-52
pubmed: 17548692
Am J Epidemiol. 2008 Mar 15;167(6):684-91
pubmed: 18222934
Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S52-61
pubmed: 18504708
BMC Cancer. 2010 May 26;10:238
pubmed: 20504360
Nutr Metab (Lond). 2010 May 27;7:46
pubmed: 20504373
Cancer Manag Res. 2009 Apr 03;1:25-37
pubmed: 21188121
Endocr Relat Cancer. 2014 May 06;21(3):R209-25
pubmed: 24500760
PLoS One. 2014 Feb 25;9(2):e89806
pubmed: 24587049
Nat Rev Drug Discov. 2014 Jul;13(7):513-32
pubmed: 24981364
Oncotarget. 2015 Jul 10;6(19):17570-83
pubmed: 25999350
Nutr J. 2015 Jun 19;14:62
pubmed: 26085034
Mol Med Rep. 2015 Nov;12(5):7221-6
pubmed: 26398440
PLoS One. 2017 Jan 12;12(1):e0169854
pubmed: 28081224
Exp Ther Med. 2017 Jun;13(6):2939-2945
pubmed: 28587364
Oncol Lett. 2018 Aug;16(2):1579-1583
pubmed: 30008840
Lancet. 1993 Apr 24;341(8852):1103-4
pubmed: 8097009
Genes Dev. 1996 Jun 15;10(12):1443-54
pubmed: 8666229
Science. 1997 Jan 10;275(5297):218-20
pubmed: 8985016